Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.

Nat Commun · 2021 · PMC8211846 · PMID 34140482

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

marginally significantP = 0.051so close (0.05 < p ≤ 0.1)

In contrast to 30 mg QD dacomitinib and 80 mg QD osimertinib, we observed a marginally significant improvement after 1 year of treatment ( P = 0.051) after multiple comparison corrections.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.